Navigation Links
Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
Date:9/8/2008

in any dose cohort after 14 days of dosing.

In a 4-week Phase 1 combination study that was conducted in 81 treatment-naive patients chronically infected with HCV genotype 1, R7128 demonstrated significant short-term antiviral activity with safety and tolerability comparable to placebo with SOC. Results from the 500mg, 1500mg and 1000mg dose cohorts (cohorts 1, 2 and 3) in 81 treatment-naive patients chronically infected with HCV genotype 1 indicated:

Preliminary results with R7128 1000mg BID with SOC indicated patients achieved a mean 5.0 log10 IU/mL decrease in HCV RNA and 88% (22 of 25) patients achieved RVR.

Results with R7128 1500mg BID with SOC indicated patients achieved a mean 5.1 log10 IU/mL decrease in HCV RNA and 85% (17 of 20) patients achieved RVR

Results with R7128 500mg BID with SOC indicated patients achieved a mean 3.8 log10 IU/mL decrease in HCV RNA and 30% (6 of 20) patients achieved RVR.

Results with placebo with SOC indicated patients achieved a mean 2.9 log10 IU/mL decrease in HCV RNA and 18.75% (3 of 16) patients achieved RVR

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with HCV. The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
2. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
3. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
4. Pharmasset Joins Russell 3000 Index
5. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
6. Pharmasset Selected to Join the NASDAQ Biotechnology Index
7. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
8. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
9. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
10. Pharmasset Receives $10 Million of Working Capital
11. Pharmasset Appoints Herbert J. Conrad as a Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... PRC Clinical, a Clinical ... the ACRP 2015 Global Conference and Exhibition on April ... of Clinical Research Professionals (ACRP) Global Conference and Exhibition ... on the conduct of clinical trials. ACRP supports clinical ... recognized industry certifications. , The ACRP 2015 Global ...
(Date:4/21/2015)... Thornton Cleveleys (UK) (PRWEB) April 21, 2015 ... PEEK* technology and its clinical applications will ... Meeting. Participants include engineers, scientists, regulators and ... worldwide. The meeting is sponsored by Invibio ... PEEK polymer-based biomaterials, a specialist in manufacturing ...
(Date:4/21/2015)... April 21, 2015 YourEncore, an ... life sciences, consumer products and food sciences industries ... the Alliance for Clinical Research Excellence and Safety ... for conducting clinical research, have partnered to speed ... , YourEncore brings to ACRES experts with ...
(Date:4/20/2015)... Winston-Salem, NC and Champaign, IL (PRWEB) April 20, 2015 ... announced today the establishment of its 12th clinical research ... 2015, PMG Research has assumed operation of the clinical ... IL, expanding PMG’s footprint outside the Southeast to a ... site within a 150 multi-specialty physician practice enhances PMG’s ...
Breaking Biology Technology:PRC Clinical Sponsors The ACRP 2015 Global Conference And Meets Biotech Companies in the Salt Lake City Area. 22nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 22nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 3YourEncore and ACRES Partner to Drive Innovation in Clinical Research 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 3PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 2PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 3
... Engineers at the University of California, Berkeley, have ... could one day give new meaning to the term ... material that functions like the human skin, which means ... Ali Javey, associate professor of electrical engineering and computer ...
... Trial Amended ... ... var shortURL = ""; ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; ...
... Inc. today announced the Company,s lead product, PTK ... of several poster presentations at the 50th Interscience ... Stuart Levy, co-founder and Chief Scientific Officer of ... a symposium on antibiotic resistance at the conference. ...
Cached Biology Technology:Engineers make artificial skin out of nanowires 2Engineers make artificial skin out of nanowires 3Resverlogix's Phase 2 ASSURE Trial Amended 2Resverlogix's Phase 2 ASSURE Trial Amended 3Resverlogix's Phase 2 ASSURE Trial Amended 4Resverlogix's Phase 2 ASSURE Trial Amended 5Resverlogix's Phase 2 ASSURE Trial Amended 6Resverlogix's Phase 2 ASSURE Trial Amended 7Paratek to Present Clinical Data at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek to Present Clinical Data at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy 3
(Date:4/1/2015)... --  Medisafe ™, the leading global medication management platform ... and Android smartphones and tablets, announces today ... to allow patients to track and correlate their adherence ... will be able to visualize in real-time how taking ... as glucose levels and blood pressure. "Patients ...
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... the "Global Gesture Recognition Market in Automotive Sector ... analysts forecast the Global Gesture Recognition market in Automotive ... the period 2013-2018. Gesture recognition is the ... different gestures of an individual. Gesture recognition technology can ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition ... Report" report to their offering. This report analyzes ... by the following Segments: Face Biometrics, and Voice Biometrics. The report ... , Japan , Europe , ... & Africa , and Latin America ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... College of Rheumatology has released the first classification criteria ... patients with this condition, which occurs in persons aged ... pain in the shoulders, neck and hips along with ... Polymyalgia rheumatica is a relatively common cause ...
... and Shenzhen, China Novo Nordisk, one of ... BGI, the world,s largest genomics organization jointly announced ... a global collaboration framework, which provides an unprecedented ... accelerate their growth, execute their global partnering strategy ...
... by a leading University of Nottingham scientist has helped reveal ... of the early mammalian embryo. A team led by ... device in the form of a soft polymer bowl which ... the embryo implants. The research has been published in the ...
Cached Biology News:American College of Rheumatology releases first classification criteria for polymyalagia rheumatica 2Artificial 'womb' unlocks secrets of early embryo development 2
Request Info...
... a clone of the human Topoisomerase II gene. ... the topological state of nucleic acids by passing ... which generates a separate DNA helix (1,2) . ... mechanism, the enzyme can relax negatively or positively ...
Request Info...
... Stem Cell Expansion Kit - Neurosphere is a ... stem cell expansion as neurospheres in a serum ... N-2 Plus Media Supplement, which has been optimized ... et al . (1996) Genes & Development ...
Biology Products: